| Website | gbsventures.com.au |
| Phone | 61-3-8650-9900 |
| Employees | |
| Description | Life science venture capital group |
| ABT, 8/98 | $42.5M |
GBS Venture Partners (GBS) is a leading life science venture capital group resulting from a November 2002 management buyout of Rothschild Bioscience Managers Limited from NM Rothschild & Sons (Aust) Ltd.
| Company | Date | Round | Size | Participants |
| Uptake Medical | 2/12 | Series C | $35M | 7 |
| AirXpanders | 1/12 | Series D | $10M | 4 |
| Spinifex Pharmaceuticals | 8/11 | Series B | $19M | 3 |
| Pathway Therapeutics | 5/11 | Series A | $7.5M | 2 |
| CoDa Therapeutics | 4/11 | Series B | $19.2M | 3 |
| Euthymics Bioscience | 3/11 | Series A | $4M | 4 |
| AirXpanders | 3/11 | Unattributed | $5M | 1 |
| NeuroVista | 8/10 | Unattributed | $16.5M | 4 |
| Nuon Therapeutics | 8/10 | Unattributed | $10M | 3 |
| Pathway Therapeutics | 8/10 | Series A | $4.5M | 3 |
| Euthymics Bioscience | 7/10 | Series A | $24M | 2 |
| Uptake Medical | 7/10 | Series B | $17.5M | 6 |
| Xenome | 4/10 | Unattributed | $10M | 2 |
| Nuon Therapeutics | 3/10 | Unattributed | $6.05M | 3 |
| Pathway Therapeutics | 10/09 | Series A | $2.4M | 2 |
| KaloBios Pharmaceuticals | 12/08 | Series D | $12M | 8 |
| Pathway Therapeutics | 6/08 | Series A | $9.6M | 2 |
| NovaSys | 5/08 | Unattributed | $49.5M | 10 |
| Nuon Therapeutics | 7/07 | Series A | $5M | 1 |
| Phenomix | 3/07 | Series C | $55M | 10 |
| OPAL Therapeutics | 10/05 | Series A | $6M | 4 |
| Hatchtech | 5/05 | Unattributed | $2.2M | 5 |